

27 May 2020

## Investor Update Webinar

## Wednesday 3rd June 12.30 – 1.45pm

**Wednesday 27 May 2020, Opyl Limited** (ASX:OPL) today announced that it will hold an investor webinar on Wednesday 3rd June 2020 at 12.30pm, presented by Michelle Gallaher, CEO, to discuss progress within the business and provide information regarding the outlook for the coming 6-12 months.

The Management team and Board of Directors have reviewed and approved a presentation on the following topics:

- Company overview
- Global organisational structure
- Service overview
- Research and development overview
- Scale and commercialisation strategy
- Financial review
- Market opportunity
- COVID19 impact

The webinar will be live and investors are welcome to submit questions before the webinar to <u>info@opyl.ai</u>. The webinar platform allows investors to publicly type in questions in real time. If questions are not answered directly in the webinar, Michelle Gallaher, CEO will answer questions through the public forum directly after the webinar.

#### Webinar details

#### Date: Wednesday 3rd June 2020

# Time: 12.30 AEST: 10.30am AWST; 12.00pm ACST

# Please register to attend the webinar at <u>https://Opyl.webinarninja.com/live-webinars/358994/register</u>

Once you have registered to attend the webinar, you will receive a confirmation email with the link and log in details.

The Board has authorised this announcement for release to the ASX.

#### -ENDS-

For media enquiries: Laura Blue +61 416 699 925 For investor enquiries: info@opyl.ai www.opyl.ai

Opyl is a new generation company working at the intersection of artificial intelligence, social media and healthcare. Our focus is on developing digital tools that improve the healthcare experience for patients, deliver deep market insights from social media data and improve the efficiency and value of the clinical research process.



Our point of difference is the deep healthcare marketing and data science expertise of our diverse team and our understanding of real world data, particularly patient reported outcomes (PRO) and the value of continuous data and dialogue stream within social media.

Follow Opyl on Twitter (@Opylai), LinkedIn and Facebook